Insmed Incorporated is a biopharmaceutical company headquartered in Bridgewater, New Jersey, specializing in the development and commercialization of therapies for rare and serious diseases. The company’s lead product, Arikayce (amikacin liposome inhalation suspension), is approved for the treatment of Mycobacterium avium complex (MAC) lung disease in adults who have limited or no alternative treatment options. Insmed’s work in developing inhaled and targeted therapies underscores its commitment to addressing high unmet medical needs in pulmonary and systemic rare diseases.
In addition to its marketed product, Insmed has built a pipeline of clinical-stage candidates aimed at improving outcomes for patients with serious respiratory conditions. Among these is brensocatib, an investigational treatment for non-cystic fibrosis bronchiectasis, which is being evaluated for its ability to inhibit neutrophil serine proteases and reduce lung inflammation. The company is also advancing preclinical programs that leverage its expertise in drug delivery and formulation to pursue novel approaches in other therapeutic areas.
Founded in the late 1980s and formerly known as Transave, Insmed adopted its current name in the early 2000s as it refocused its business on rare diseases. The company completed its initial public offering in 2013, raising capital to support late-stage development of key programs. Over time, Insmed has formed strategic collaborations and in-licensed assets to broaden its pipeline and position itself as a leader in rare disease research.
Insmed’s operations extend beyond the United States, with regulatory interactions and development activities in Europe, Japan and other regions where rare pulmonary and systemic diseases pose significant healthcare challenges. Under the leadership of Chief Executive Officer Will Lewis, the company continues to invest in clinical research, manufacturing capabilities and global commercial infrastructure to bring new treatment options to patients in need.